Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Well done all holders, great news by GM and the team. This is phenomenal news, just sit back and relax and let the sp take care of itself. Revenue now is higher than mcap, this will readjust. 85% margins, NPT testing for hospitals and a new antibody test. We are still to here more on NPT testing for care homes, versalab and prometa. Sales continue all around the world too. This will easily be a £1b+ mcap and a good chance much higher. Enjoy the rerate.
Saintpeter - I think honestly this is a £1b mcap company in the making at the minimum, which is 2x here. Just look at other big diagnostic companies which are 10x that size and check their profits and compare to what NCYT is doing. These are strange times and NCYT in this current climate £1b is truly game on, and slightly conservative. There is potential for much more, but we can only see what is currently in front of us. 6 months ago we had people shouting that a 50m mcap was way to high and were shorting accordingly. My personal target, until new info comes in on further progress, is £12-16.
Firstly well done those clever lads and lasses at NCYT and all their hard work. Most are just getting caught up in the Q16/Q32 machines, but its much bigger than that. Initial rollout is planned to do 60,000 tests a day. Whose kit will they be using, yep primerdesign, this alone equates to 1.8m tests a month for them for the foreseeable future. Now that is just for hospitals, we have the care home trial results to come (remember they were testing at hospitals and at care homes with Queen Mary Uni - and results were due today), and we also have the standard PCR tests at the lighthouse labs. And the great thing is that is just the UK! We are distributing to over 160 countries now - just like we saw that order from Hungary a few days ago for 5-6m, they'll be many many more. This company has been handled so well by GM and the team, no jam tomorrow constant delivering on targets, and expanding rapidly but intelligently. This deserves to be a £1b mcap at the least. Add to that we have more to here on Versalabs and Prometa and the antibody test. Well done holders and a special well done to the NCYT team
Back on the 21st May I responded to him
"John_james we've had some truly inept posts on this board over the course over the last few months, but that one is right up there with the very best of the top stupid posts we've had."
It looks like he was trying to cause trouble back then, and boy his post must have been stupid for me to write that.
This share is unusual to us aim dwellers, that this stock is primarily driven by our baguette loving friends. We saw that when the SP shot down with the non-reimbursement RNS a few months ago. Today we've had confirmation that Winterplex is to be reimbursed by those lovely onion loving bastards. That confirmation is much bigger than we think. Just as we Brits get more excited by something home grown (check Alba Welsh gold and who can forget UKOG). But this company is something different, its well run, at a moment in time when something highly unusual is happening, and delivers, time after time after time. None of the normal aim shenanigans about selling the story of what we have, as there is no need as GM and co just deliver. None of the normal promise under deliver **** that is aim (note GDR's RNS today). I'm sorry to GDR and AVCT holders here but all their CEO is do is promise the magic carrot, I've seen that so many times and 9/10 on AIM it doesn't deliver, the donkey forever chases, keep that donkey chasing long enough and you may be able to get more money out of it. NCYT is one of those rare aim gems. Hold, be rewarded for once in this dodgy world.
5 companies been used in Hungary including Primerdesign for the purchase of 2m tests (total of £24m). Every little helps.
https://nepszava.hu/3093123_9-6-milliard-forintert-vett-covid-teszteket-a-magyar-allam-es-peldaul-ingatlanertekesito-cegtol-is-vasarolt
NCYT will defo be above £10+ in the not to distant future. A good company that finally got unfortunately the chance to shine. And boy it shines. Not one missed deadline, debt free, huge profits incoming, transformational. The fact its considered in diagnostic papers about covid about who the big players are, its at the table. That table its sat around are all multi-billion mcap players......and NCYT........No others are valued that cheap when they consider the WHO's who of testing. Still so cheap here. I certainly expect some big jumps in SP here in the coming weeks. I would be shocked if not over well over £10 by Oct/Nov.
Our Stan, maybe just be a little bit more worried about AVCT than NCYT. AVCT have a mcap 50% higher than NCYT - all that rise is factored in on its game changing test that it announced 6 months ago, and still no sign of it. Boris even said last week that pregnancy style tests were unfortunately not going to be ready any time soon. And as AVCT drag their heels, suddenly there is loads of competition on this style of test coming, GSK Crispr test, Abbotts LFT, Mologic's 15min antigen test - and more than likely NCYT's LFT test coming soon. Unfortunately AVCT's base is built on sand, if the test isn't great the whole affirmer tech becomes more questionable. Of course we need other types of tests, and it won't be all done by PCR, but PCR will be the backstop for all testing as its the most accurate. NCYT have been selling tests now for nearly 6 months, building cash and transforming the company so that it can expand into many other areas of diagnostics. GM outlook as normal was conservative, he is the opposite of AS at AVCT. Under promise and over deliver is what GM has done all along. I hope AVCT does well, I hold a small amount from the 50's, but it seems to me much higher risk than NCYT with less upside and far more downside potential.
Tee hee, our Stan and 9inch are back. Stan who bought so late into AVCT he missed most of the rise, and 9inch who sold out of NCYT at 40p and has been claiming over priced ever since. Lovely to see you chaps, portfolio going well then.
Lovely to know that NCYT are about to bring out antibody test within a couple of weeks, NPT results for mobile PCR testing within a week, and 2 new surprise tests - cough microgen, cough cough, LTF multiplex. Ahem. 7 months since NCYT released the first cv19 test and AVCT still haven't got a test out. NCYT have released 5 improved tests since then with more to follow. Don't get me wrong there is lots of room for a lot of CV tests out there and for there mcaps to grow, but anyone who thinks NCYT is over valued is having a laugh (especially whilst Stan is still drooling over AVCT's potential without a test and a higher mcap and yet somehow doesn't see the irony). I could go on, but great to see you back chaps.
I think its because we got a new broker that these results were published. The most significant part that this projection is without any major tender wins included - any of those will blow the revenues through the roof. Also 85% margin is way way higher than most here were expecting (50-60% was what most were thinking). Lovely stuff.
Tom - if you actually read up you'd realise there are 7 lighthouse labs, most of the workers are provided by GSK, Astra, Perkin Elmer and other large pharma companies. Also you'd also realise that the work is rapidly becoming automated so that fewer workers are needed.
Please see link here, looks like NHS asked Primerdesign for mulitplex - I smell a large tender incoming.
https://www.rcpath.org/uploads/assets/9c674b06-f1b7-455a-a19ae77d99cf22a8/Testing-Methods-Bulletin-9-24-July.pdf
Just appointed a Head of Government Sales - UK & Ireland at Novacyt Group. Now why would they need to do that.
https://www.linkedin.com/in/samantha-stuart-8790b079/